Century Therapeutics, Inc.
IPSC
$1.17-0.15 (11.36%)Nov 20
After-hours: $1.17 (-0.43%)
Century Therapeutics, Inc. (IPSC)
$1.17-0.15-11.36%Nov 20
Loading chart…
USA›Health Care›Biotechnology›Biotechnology
YTD17%
M.cap.212 mn
Std.Dev, 1y-1.33
Vol, bn0.0 (med)
RSI39
P/E—
MFI51
P/S—
ADX26 (trend)
P/B1.01
Beta1.79
Div—
Debt/EBITDA12.62
Payout—
Price target
Buy 2 (67%)Hold 1 (33%)Sell 0 (0%)
Next earnings—
Earnings surprise
Short interest31.6% (+2.9%), 30 Oct 2026
Fund owners #60 (-48)
Insider ownership$8 mm
Insider sellingMedium
Insider buying—
General
M.Cap$212M
Dividends—
Next report—
Forecast
Valuation
Target
P/E—
P/S—
P/B1.01
Fundamentals
5-y avg sales growth+0.0%
Debt / EBITDA12.62
ROE—
Altman Z-score-3.35 (distress)
Technicals
RSI39
MFI51
Price / MA50-26.3% (v.low) ↓
Trend pattern
Financial Statements
No data available
Financial Statements
No data available
Team
Loading…
Team
Loading…
Leadership Changes
Sign in to view leadership changes
Sign in
No changes found
Insider Activity
Loading…
Insider Activity
Loading…
DateTypeDescription
Loading…
Earnings Transcripts
Loading…
Earnings Transcripts
Loading…
Dividends
Loading…
Dividends
Loading…
Investor Presentations
Loading…
Investor Presentations
Loading…
Options
Exp. from:to:
Strike from:to:
Loading…
Options
Expiration from:
to:
Strike from:
to:
Loading options…
Loading bonds…
Stress Test
Loading…
Stress Test
Loading…
About

Century Therapeutics develops allogeneic cell therapies to treat various types of cancers, focusing on solid tumors and hematological malignancies. Its lead product is CNTY-101, an allogeneic CAR-iNK cell therapy that targets CD19 for relapsed B-cell lymphoma. The company has also developed several other product candidates for different types of cancers.

Headcount: 78
Address:25 North 38th Street, Philadelphia, PA, United States, 19104
About

Century Therapeutics develops allogeneic cell therapies to treat various types of cancers, focusing on solid tumors and hematological malignancies. Its lead product is CNTY-101, an allogeneic CAR-iNK cell therapy that targets CD19 for relapsed B-cell lymphoma. The company has also developed several other product candidates for different types of cancers.

https://www.centurytx.com
Beta 1.79